Pharma: Page 16
-
Md Saiful Islam Khan via Getty Images
AstraZeneca, Daiichi aim for first pan-tumor ADC approval
A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates.
By Ben Fidler • Jan. 29, 2024 -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Dan Kitwood/Getty Images via Getty Images
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.
By Michael Gibney • Jan. 25, 2024 -
Stock via Getty Images
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Stock via Getty Images
Breast cancer tops list of most studied diseases
The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.
By Kelly Bilodeau • Jan. 24, 2024 -
Mike Coppola via Getty Images
J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff
Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.
By Michael Gibney • Jan. 24, 2024 -
Getty Images via Getty Images
The hunt for an elusive universal coronavirus vaccine
A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.
By Alexandra Pecci • Jan. 22, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
iStock via Getty Images
How to make 2024 a banner year for biopharma, despite the headwinds
Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.
By Michael Gibney • Jan. 18, 2024 -
Getty Images via Getty Images
An enduring COVID mystery: Why some do fine and others die
The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.
By Alexandra Pecci • Jan. 17, 2024 -
Stock via Getty Images
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Stock via Getty Images
OpinionPharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
iStock via Getty Images
4 big FDA approval dates to watch in 2024
Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals.
By Alexandra Pecci • Jan. 12, 2024 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
Shutthiphong Chandaeng via Getty Images
Believe the hype? Mixed signals from AI’s impact on drug development
Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.
By Kelly Bilodeau • Jan. 10, 2024 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Perspectives on the financial future
Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.
By Meagan Parrish • Jan. 9, 2024 -
Stock via Getty Images
Regulatory twists and turns are coming for biopharma in 2024
New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.
By Kelly Bilodeau • Jan. 8, 2024 -
E+ via Getty Images
How J&J is tackling a ‘secondary pandemic’ in the Black community
J&J is leading a grassroots effort to improve mental health access and care.
By Alexandra Pecci • Jan. 8, 2024 -
iStock via Getty Images
In the post-pandemic era, three players still dominate the infectious disease market
While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.
By Alexandra Pecci • Jan. 5, 2024 -
iStock via Getty Images
Alzheimer’s research is hot, but successful patient recruitment will determine its future
Key strategies for bringing more patients into the clinical trial fold.
By Kelly Bilodeau • Jan. 4, 2024 -
iStock via Getty Images
Pharma’s financial market will be a tale of two cities in 2024
What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”
By Kelly Bilodeau • Jan. 4, 2024 -
Justin Sullivan via Getty Images
Why J&J rebranded its iconic logo
J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.
By Alexandra Pecci • Jan. 3, 2024 -
Stock via Getty Images
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
LD via Getty Images
Biopharma’s FTC headache deepens with guideline shifts years in the making
Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.
By Michael Gibney • Dec. 21, 2023 -
Stock via Getty Images
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023
Previous
